Richard A. Heyman - Feb 13, 2024 Form 4/A Insider Report for Enliven Therapeutics, Inc. (ELVN)

Role
Director
Signature
/s/ Ben Hohl, by power of attorney
Stock symbol
ELVN
Transactions as of
Feb 13, 2024
Transactions value $
$0
Form type
4/A
Date filed
2/20/2024, 07:32 PM
Date Of Original Report
Feb 15, 2024
Previous filing
Feb 1, 2024
Next filing
Feb 20, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ELVN Stock Option (right to buy) Award $0 +29.2K $0.00 29.2K Feb 13, 2024 Common Stock 29.2K $14.85 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The original Form 4 filed February 15, 2024 incorrectly reported the number of shares subject to the option grant.
F2 100% of the shares subject to the option will vest on the earlier of (i) the first anniversary of the 2024 annual meeting of the Issuer's stockholders or (ii) the date of the 2025 annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing as a non-employee director on the applicable vesting date.